| GI CANCER: ORIGINAL ARTICLE
|Year : 2020 | Volume
| Issue : 2 | Page : 158-163
An analysis of adjuvant treatment strategies in operated pancreatic cancer patients: An Izmir oncology group study
Umut Varol1, Yusuf Uzum2, Adem Sengul3, Ugur Bayram Korkmaz2, Murtaza Parvizi4, Murat Akyol4, Halil Taskaynatan1, Tarik Salman1, Utku Oflazoglu1, Yasar Yildiz1, Ahmet Alacacioglu1, Yuksel Kucukzeybek1, Mustafa Oktay Tarhan5
1 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
2 Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
3 Department of Radiation Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
4 Department of Oncology Clinic, Manisa Government Hospital, Manisa, Turkey
5 Department of Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
Background: Adjuvant treatment is necessary in pancreatic cancer patients, but the optimal approach is not clear yet. Our aim was to explore the effectiveness of adjuvant treatment modalities in patients with operated pancreatic cancer.
Methods: There were five groups of patients operated for primary pancreas adenocarcinoma. The first two groups included patients who were treated with only adjuvant chemotherapy or radiotherapy. The patients in third group had received combination chemotherapy and radiotherapy either sequentially or concomitantly. The fourth group was composed of patients who were treated with adjuvant chemotherapy after concurrent chemoradiotherapy, whereas the patients in the fifth group were only observed after surgery without any adjuvant treatment.
Results: There were 83 operated pancreatic cancer patients available for analysis. Median age of the patients was 63 years (range, 40–82 years). There were 55 patients who had local disease recurrence (n = 14) or metastasis (n = 41) during or after adjuvant treatment. The median overall survival for all patients was 14 months. When we compared the median survival of patients who had any adjuvant treatment with the patients treated without any adjuvant therapy, we found a significant statistical difference between the groups (32.4 vs 6.5 months; P = 0.000). In addition, survival of each treatment group was also compared with each other but we did not find any significant statistical difference.
Conclusions: Our result suggests that any adjuvant therapy in the treatment of pancreatic cancer patients is important. However, we could not find any superiority between adjuvant treatment modalities.
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*